#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2025 - 6

Modern possibilities of diagnosis and treatment of Peyronie's disease in the Czech context

Czech version

Authors: Marek Broul 1-3;  Aneta Hujová 3;  Libor Zámečník 4,5
Authors‘ workplace: Sexuologické oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z. 1;  Urologické oddělení, Krajská zdravotní, a. s. – Nemocnice Litoměřice, o. z. 2;  Fakulta zdravotnických studií UJEP v Ústí nad Labem 3;  Sexuologický ústav 1. LF UK a VFN v Praze 4;  Urologická klinika 1. LF UK a VFN v Praze 5
Published in: Čas. Lék. čes. 2025; 164: 262-268
Category: Review Article

Overview

Peyronie's disease is an acquired fibrotic disorder of the tunica albuginea, leading to penile deformity, painful erections, and often erectile dysfunction; its prevalence in Europe reaches up to 9% in middle-aged men. This review summarizes the results of studies from 2019–2025 concerning diagnostic methods and therapeutic options.

Based on the analysis of 142 original studies, 23 meta-analyses, and current European Association of Urology (EAU) a American Urological Association (AUA) recommendations, we confirm that intralesional verapamil reduces curvature in the active phase by an average of 9–17° and low-intensity shockwave therapy (LiSWT) improves pain and reduces curvature by approximately 10°, particularly for plaques larger than 2 cm. Surgical methods –⁠ plication, incision/grafting, and penile prosthesis implantation –⁠ achieve initial straightening in more than 90% of cases but differ in impact on penile length and the risk of de novo erectile dysfunction. Regenerative therapies like platelet-rich plasma (PRP) or mesenchymal stem cells (MSC) offer promising, yet currently experimental results.

Optimal care is based on early diagnosis, individualization of conservative treatment, and precise surgical correction; in the Czech Republic, standard approaches include verapamil, LiSWT, and surgery, while biological approaches require further research.

Keywords:

regenerative medicine – Peyronie’s disease – intralesional verapamil – low intensity shock wave therapy – surgical plication – grafting – penile prosthesis

Sources
  1. Sandean DP, Leslie SW, Lotfollahzadeh S. Peyronie disease. StatPearls, Treasure Island, 2025. Dostupné na: www.ncbi.nlm.nih.gov/books/NBK560628
  2. Mitsui Y, Yamabe F, Hori S et al. Molecular mechanisms and risk factors related to the pathogenesis of Peyronie’s disease. Int J Mol Sci 2023; 24 : 10133.
  3. Lethuillier V, Peyronnet B, Richard C et al. When fibrosis intersect: Association and risk factors between Peyronie’s and Dupuytren’s diseases. Fr J Urol 2024; 34 : 102759.
  4. Karakus S, Unal S, Dai D al. Early-onset and uncontrolled diabetes mellitus factors correlate with complications of Peyronie’s disease. J Sex Med 2024; 21 : 716–722.
  5. Chi J, Bi W, Lou K et al. Research advances in Peyronie’s disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. Sex Med Rev 2024; 12 : 477–490.
  6. Henningsohn L, Larsson H, Kuja-Halkola R, Cederlöf M. Risk of relationship separation in men with Peyronie’s disease in a matched Swedish cohort. Sci Rep 2024; 14 : 21143.
  7. Salonia A, Capogrosso P, Boeri L et al. European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie’s disease. Eur Urol 2025; 88 : 76–102.
  8. Schwarzer U, Sommer F, Klotz T et al. The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001; 88 : 727–30.
  9. Tal R, Heck M, Teloken P et al. Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med 2010; 7 : 1254–1261.
  10. Gianazza S, Belladelli F, Leni R et al. Peyronie’s disease development and management in diabetic men. Andrology 2023; 11 : 372–378.
  11. EAU Guidelines on Sexual and Reproductive Health. European Association of Urology, 2025. Dostupné na: https://uroweb.org/guidelines/sexual-and-reproductive-health
  12. Traeger M, Leiber-Caspers C, Chierigo F et al. Penile autophotography underestimates the degree of penile curvature in Peyronie’s disease. Eur Urol Focus 2023; 9 : 64–68.
  13. Wattamwar GK, Onkar P, Phatak SV, Mitra K. High-frequency ultrasound in Peyronie’s disease: a case series. J Med Ultrasound 2025; 33 : 77–81.
  14. Bertini A, Pozzi E, Belladelli F et al. Penile curvature severity in patients with Peyronie’s disease does not correlate with dynamic color doppler duplex ultrasound parameters: findings from a real-life cross-sectional study. Andrology 2024; 13 : 1462–1468.
  15. Zhao S, Wu X, Zhang Y, Zhang C. Role of shear wave elastography in the diagnosis of Peyronie disease. J Ultrasound Med 2024; 43 : 397–403.
  16. De Rizzo RH, Gonzales GC, Cortines HR et al. The role of the Peyronie’s disease questionnaire in translation, cultural adaptation, and treatment management for Portuguese-speaking populations. Cureus 2024; 16: e76242.
  17. Hellstrom WJG, Feldman R, Rosen RC et al. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s Disease Questionnaire. J Urol 2013; 190 : 627–634.
  18. Gelbard M, Goldstein I, Hellstrom WJG et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in two large double-blind, randomized, placebo-controlled phase 3 studies. J Urol 2013; 190 : 199–207.
  19. Lipshultz LI, Goldstein I, Seftel AD et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int 2015; 116 : 650–656.
  20. Guo Y, Yang Y, Mao Q et al. Efficacy of collagenase Clostridium histolyticum combination therapies for Peyronie’s disease: a systematic review and meta-analysis. Sex Med Rev 2024; 12 : 497–504.
  21. Chung E, Wang J. Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie’s disease: a prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates. Investig Clin Urol 2022; 63 : 563–568.
  22. Trost LW, Ates E, Powers M et al. Outcomes of intralesional interferon-α2b for the treatment of Peyronie disease. J Urol 2013; 190 : 2194–2199.
  23. Sokhal AK, Jain NK, Jhanwar A et al. Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie’s disease. Urol Ann 2018; 10 : 154–158.
  24. Abdel Fattah AAE, Diab T, El-Dakhakhny AS, El Hamshary SA. Intralesional injection of hyaluronic acid compared with verapamil in acute phase of Peyronie’s disease: a prospective randomized clinical trial. Arab J Urol 2022; 22 : 206–211.
  25. Broul M, Schraml J, Štrbavý M et al. The findings gained from the application of verapamil into the plaque of patients suffering from induratio penis plastica (IPP) –⁠ Morbus Peyronie. J Sex Med 2017; 14 (Suppl. 4b): e332–e332.
  26. Broul M, Schraml J, Hokůvová P. Injection of verapamil into the plaque of patients with induratio penis plastica (IPP) –⁠ Morbus Peyronie. Arab J Urol 2018; 16 (Suppl. 1): S37–S38.
  27. Broul M, Hokůvová P, Schraml J. Zkušenosti s aplikací verapamilu do plaku u pacientů s induratio penis plastica –⁠ morbus Peyronie. Urol Praxi 2018; 19 : 29–32.
  28. Zámečník L. Neinvazivní nechirurgická léčba plastické indurace penisu. Urol Praxi 2015; 16 : 21–24.
  29. Lee HY, Pyun JH, Shim SR, Kim JH. Medical treatment for Peyronie’s disease: systematic review and network Bayesian meta-analysis. World J Mens Health 2024; 42 : 133–147.
  30. Paulis G, Brancato T, D’Ascenzo R et al. Efficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 cases. Andrology 2013; 1 : 120–128.
  31. Seftel AD. Re: Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. J Urol 2016; 195 : 1562–1564.
  32. Joseph J, Ziegelmann MJ, Alom M et al. Outcomes of RestoreX penile traction therapy in men with Peyronie’s disease: results from open-label and follow-up phases. J Sex Med 2020; 17 : 2462–2471.
  33. Ziegelmann M, Toussi A, Savage J et al. 6-month outcomes with RestoreX penile traction system in men with Peyronie’s disease: a randomized, controlled trial. J Urol 2020; 203 (Suppl. 4): e500–e501.
  34. Ziegelmann M, Savage J, Toussi A et al. Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J Urol 2019; 202 : 599–610.
  35. Hayat S, Brunckhorst O, Alnajjar HM et al. A systematic review of non-surgical management in Peyronie’s disease. Int J Impot Res 2023; 35 : 523–532.
  36. Li G, Xu X, Man L. Low-intensity extracorporeal shock wave therapy for Peyronie’s disease: a systematic review and meta-analysis. BMC Urol 2024; 24 : 217.
  37. Rassweiler JJ, Scheitlin W, Goezen AS, Radecke F. Long-term experiences with high-energy shock wave therapy in the management of chronic phase Peyronie’s disease using two different electromagnetic lithotripters. World J Urol 2024; 42 : 124.
  38. Dell’Atti L, Slyusar V, Ronchi P, Cambise C. Vacuum erection device plus once-daily tadalafil improve clinical outcomes after extracorporeal shock wave therapy in men affected by erectile dysfunction associated with Peyronie’s disease. Life 2024; 14 : 1162.
  39. Dachille G, Panunzio A, Bizzotto L et al. Platelet-rich plasma intra-plaque injections rapidly reduce penile curvature and improve sexual function in Peyronie’s disease patients: results from a prospective large-cohort study. World J Urol 2025; 43 : 306.
  40. Wiborg MH, Krøijer R, Laursen BS et al. Treatment with autologous adipose-derived regenerative cells for Peyronie’s disease in men: the Straight @head pilot study. Eur Urol Open Sci 2025; 71 : 180–186.
  41. Feng H, Peng W, Deng Z et al. Erectile dysfunction and exosome therapy. Front Endocrinol 2023; 14 : 1123383.
  42. Ergün M, Sağır S. Low-intensity extracorporeal shock wave therapy and platelet-rich plasma: effective combination treatment of chronic-phase Peyronie’s disease. Arch Esp Urol 2025; 78 : 164–169.
  43. Kadıoğlu A, Salabaş E, Özmez A et al. Peyronie’s disease surgery: surgical outcomes of 268 cases. Turk J Urol 2018; 44 : 10–15.
  44. Fazili T, Kouriefs C, Anjum F et al. Ten years outcome analysis of corporeal plication for Peyronie’s disease. Int Urol Nephrol 2007; 39 : 111–114.
  45. Chung E, Blecher G. Perspective: Residual penile curvature correction during penile prosthesis implantation by plication in Peyronie’s patients. Int J Impot Res 2023; 35 : 643–646.
  46. Hatzichristodoulou G. Novel approaches and new grafting materials in Peyronie’s disease reconstructive surgery. Int J Impot Res 2020; 32 : 37–42.
  47. Terrier JE, Tal R, Nelson CJ, Mulhall JP. Penile sensory changes after plaque incision and grafting surgery for Peyronie’s disease. J Sex Med 2018; 15 : 1491–1497.
  48. Spinozzi L, Droghetti M, Palmisano F et al. Use of soft penile prosthesis in grafting surgery for Peyronie’s disease and mild erectile dysfunction: still an option? Arch Esp Urol 2024; 77 : 270.
  49. Sokolakis I, Pyrgidis N, Mykoniatis et al. A comprehensive narrative review of residual curvature correction during penile prosthesis implantation in patients with severe erectile dysfunction and concomitant Peyronie’s disease. Transl Androl Urol 2021; 10 : 2669–2681.
  50. Good J, Crist N, Henderson B et al. Inflatable penile prosthesis placement in Peyronie’s disease: a review of surgical considerations, approaches, and maneuvers. Transl Androl Urol 2024; 13 : 139–155.
  51. Trost L, Huang H, Han X et al. Penile surgery for patients with Peyronie’s disease initially treated with collagenase Clostridium histolyticum or surgery: a claims database analysis. Int J Impot Res 2023; 35 : 147–151.
  52. Levine LA. Treatment of Peyronie’s disease with intralesional verapamil injection. J Urol 1997; 158 : 1395–1399.
  53. Brant WO, Reed-Maldonado A, Lue TF. Injection therapy for Peyronie’s disease: pearls of wisdom. Transl Androl Urol 2015; 4 : 474–477.
  54. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 1998; 51 : 620–626.
  55. Mitsui Y, Yamabe F, Hori S et al. Molecular mechanisms and risk factors related to the pathogenesis of Peyronie’s disease. Int J Mol Sci 2023; 24 : 10133.
  56. Solakhan M, Kısacık B. Is Peyronie’s an IgG4-related disease? Eur J Rheumatol 2020; 8 : 27.

   

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Change in the prevalence of overweight, obesity and severe obesity in seven-year-old children between 2019–2023 – project COSI
Survey of experiences of chronically ill patients with care provided by general practitioners and evaluation of the outcomes of this care
Probiotics in antibiotic treatment – an overview of effectiveness, risks, and recommended practices
What to consider when sharing health information on-line?
Czech Medical Association of J. E. Purkyně honored the best medical publications of 2024
Little-known first autopsies in the Czech lands
Newly discovered documents about J. E. Purkyně at the Anatomical Institute of the 1st Faculty of Medicine, Charles University
Oldřich Ferdinand, MD – a notable figure of moravian phoniatrics. A remembrance on the 115th anniversary of his birth
His dream became reality. In memory of professor Vladimír Vonka (1930–2025).
Postoperative nausea and vomiting
The tales of new drug discoveries
Přednáškové večery Spolku českých lékařů v Praze (leden – březen 2026)
Úvodem
Article was published in

Journal of Czech Physicians

Issue 6
2025 Issue 6
Download issue PDF
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#